Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT).
Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD).
According to a news release, results from a 12-month, real-world data study of reSET-O demonstrated reduced healthcare resource utilization and associated costs for the PDT. In particular, inpatient stays, which include ICU stays and readmissions, as well as emergency department visits were reduced, contributing to a net cost reduction of $3,832 per patient for the Medicaid population, and an increase in buprenorphine adherence in patients with OUD treated with reSET-O compared to controls, based on a linear model of the medication possession ratio.
The study, which compared 901 adult patients prescribed and treated with reSET-O with 978 controls, was accepted for publication and made available via pre-print by the international peer-reviewed journal Advances in Therapy.
Compared to the control group, the reSET-O group produced a 28% reduction in inpatient stays (including a 30% reduction in ICU stays and 56% reduction in readmissions) and a 7% reduction in emergency department visits. Per-patient costs across all-payer mix by dropped by an estimated $2,791 and per-patient costs for the Medicaid population had an estimated $3,832 reduction.
Results also demonstrated that, among patients on buprenorphine therapy, adherence significantly increased among those treated with reSET-O vs controls, based on a linear model of the medication possession ratio, despite both groups having similar buprenorphine adherence at baseline.
“The data show our health economic outcomes for reSET-O now go out to 12 months, demonstrating durability of the clinical effect for opioid use disorder patients, which is an often difficult to treat patient group as shown in part by the record number of overdose deaths over the last year,” Pear Therapeutics CMO and Head of Development Dr. Yuri Maricich said in the release. “To overcome the opioid crisis, we must increase access to treatment options that may improve outcomes. The results of this analysis demonstrated that patients who were treated with reSET-O showed lower incidence of inpatient stays and emergency department visits, compared to control patients.”